Shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) have earned an average broker rating score of 2.00 (Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation.

Brokerages have set a 1 year consensus price objective of $12.00 for the company, according to Zacks. Zacks has also given Dipexium Pharmaceuticals an industry rank of 106 out of 265 based on the ratings given to its competitors.

Several analysts recently weighed in on the company. Zacks Investment Research downgraded Dipexium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Redburn Partners upgraded Dipexium Pharmaceuticals to an “outperform” rating in a research note on Tuesday, August 1st. Finally, UBS AG upgraded Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Monday, July 31st.

Dipexium Pharmaceuticals (NASDAQ:PLXP) remained flat at $$6.65 during trading on Friday. The company had a trading volume of 289 shares, compared to its average volume of 9,574. The company has a debt-to-equity ratio of 0.56, a current ratio of 8.99 and a quick ratio of 8.88. Dipexium Pharmaceuticals has a 52 week low of $5.60 and a 52 week high of $22.00.

Several institutional investors have recently bought and sold shares of PLXP. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Dipexium Pharmaceuticals in the 3rd quarter worth approximately $145,000. Susquehanna International Group LLP purchased a new stake in shares of Dipexium Pharmaceuticals in the 2nd quarter worth approximately $1,413,000. Finally, University of Texas Investment Managment Co. purchased a new stake in shares of Dipexium Pharmaceuticals in the 2nd quarter worth approximately $385,000. Institutional investors own 22.83% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/11/26/brokerages-set-12-00-target-price-for-dipexium-pharmaceuticals-inc-plxp.html.

Dipexium Pharmaceuticals Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Get a free copy of the Zacks research report on Dipexium Pharmaceuticals (PLXP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.